Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C22H27NO4.ClH.H2O |
| Molecular Weight | 423.93 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.Cl.COC1=CC2=C(C=C1OC)[C@H]3[C@@H](C)C4=C(CN3CC2)C(OC)=C(OC)C=C4
InChI
InChIKey=KBZTZEOLXUYGHE-OAOCJZEUSA-N
InChI=1S/C22H27NO4.ClH.H2O/c1-13-15-6-7-18(24-2)22(27-5)17(15)12-23-9-8-14-10-19(25-3)20(26-4)11-16(14)21(13)23;;/h6-7,10-11,13,21H,8-9,12H2,1-5H3;1H;1H2/t13-,21+;;/m0../s1
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C22H27NO4 |
| Molecular Weight | 369.4541 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | H2O |
| Molecular Weight | 18.0153 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Corydaline is a pharmacologically active isoquinoline alkaloid isolated from Corydalis tubers. It exhibits the antiacetylcholinesterase, antiallergic, antinociceptive, and gastric emptying activities. Corydaline exhibited strong nematocidal activity, showed little cytotoxicity and represents a potential treatment for Strongyloidiasis. Corydaline exhibits gastrointestinal modulatory, antinociceptive, anti-allergic, and anti-parasitic activities. Corydaline is currently in clinical trials as a potential treatment for functional dyspepsia. In animal models, corydaline increases gastric emptying and small intestine transit speed and induces gastric relaxation. In other animal models, corydaline inhibits chemically-induced pain. Additionally, this compound may inhibit mast cell-dependent smooth muscle contraction of the aorta. Corydaline also exhibits nematocidal activity against species of Strongyloides.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: GO:0070527 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27558975 |
|||
Target ID: CHEMBL220 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17574358 |
15.0 µM [IC50] | ||
Target ID: Strongyloides ratti Sources: https://www.ncbi.nlm.nih.gov/pubmed/11809332 |
|||
Target ID: CHEMBL3622 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21826053 |
1.7 mM [Ki] | ||
Target ID: CHEMBL3397 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21826053 |
7.0 mM [Ki] | ||
Target ID: CHEMBL612436 Sources: https://www.ncbi.nlm.nih.gov/pubmed/29034730 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2370 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24216274 |
4.5 mg/kg single, oral dose: 4.5 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
CORYDALINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
276 μg × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24216274 |
4.5 mg/kg single, oral dose: 4.5 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
CORYDALINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
324 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24216274 |
4.5 mg/kg single, oral dose: 4.5 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
CORYDALINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
4.34% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24216274 |
4.5 mg/kg single, oral dose: 4.5 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
CORYDALINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Cytotoxic activity of proteins isolated from extracts of Corydalis cava tubers in human cervical carcinoma HeLa cells. | 2010-12-17 |
|
| Screening of antinociceptive components in Corydalis yanhusuo W.T. Wang by comprehensive two-dimensional liquid chromatography/tandem mass spectrometry. | 2010-03 |
|
| Effects of corydaline from Corydalis tuber on gastric motor function in an animal model. | 2010 |
|
| Isoquinoline alkaloids isolated from Corydalis yanhusuo and their binding affinities at the dopamine D1 receptor. | 2008-09-25 |
|
| Rapid TLC/GC-MS identification of acetylcholinesterase inhibitors in alkaloid extracts. | 2008-05-01 |
|
| Acetylcholinesterase and butyrylcholinesterase inhibitory compounds from Corydalis cava Schweigg. & Kort. | 2007-08-15 |
|
| The combination of rat mast cell and rabbit aortic smooth muscle is the simple bioassay for the screening of anti-allergic ingredient from methanolic extract of Corydalis tuber. | 2004-08 |
|
| [Resource investigation and quality evaluation on wild Corydalis yanhusuo]. | 2004-05 |
|
| Positive cooperation of protoberberine type 2 alkaloids from Corydalis cava on the GABA(A) binding site. | 2003-04 |
|
| Formation of protoberberine-type alkaloids by the tubers of somatic embryo-derived plants of Corydalis yanhusuo. | 2001-12 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20522959
Corydaline was administered orally in a volume of
5 ml/kg for rats and 1 ml/kg for dogs.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17574358
Corydaline inhibited acetylcholinesterase in a dose-dependent manner with an IC(50) value of 15+/-3 uM.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 22:39:39 GMT 2025
by
admin
on
Mon Mar 31 22:39:39 GMT 2025
|
| Record UNII |
7EW694LZVF
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
7EW694LZVF
Created by
admin on Mon Mar 31 22:39:39 GMT 2025 , Edited by admin on Mon Mar 31 22:39:39 GMT 2025
|
PRIMARY | |||
|
6020-22-0
Created by
admin on Mon Mar 31 22:39:39 GMT 2025 , Edited by admin on Mon Mar 31 22:39:39 GMT 2025
|
PRIMARY | |||
|
73425428
Created by
admin on Mon Mar 31 22:39:39 GMT 2025 , Edited by admin on Mon Mar 31 22:39:39 GMT 2025
|
PRIMARY | |||
|
m3801
Created by
admin on Mon Mar 31 22:39:39 GMT 2025 , Edited by admin on Mon Mar 31 22:39:39 GMT 2025
|
PRIMARY | Merck Index |